ANIP
ANI Pharmaceuticals, Inc.
Nasdaq · usd
ANI Pharmaceuticals, Inc. (ANIP) trades at $72.61 (-1.55%) as of 5:53:17 PM EDT on Oct 23, 2026, -1.93% over the past month. Market cap is $1.69B, with 7.2 days to cover in short interest.
Stock performance
How ANI Pharmaceuticals, Inc. (ANIP) stock has performed from one day to one year, with its 52-week range.
- 1D
- -1.55%
- 1W
- +0.44%
- 1M
- -1.93%
- YTD
- -8.02%
- 1Y
- -22.95%
- 52-wk range
- $69.58 – $97.00
Key statistics
Today's trading snapshot for ANIP: day range, open, previous close, volume and market cap.
- Day range
- $72.05 – $73.42
- Open
- $73.30
- Prev close
- $73.75
- Volume
- 315.34K
- Market cap
- $1.69B
- Shares out
- 22.96M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for ANI Pharmaceuticals, Inc.: P/E, P/S, P/B, ROE and more.
- P/E
- 17.01
- P/S
- 1.73
- P/B
- 2.84
- P/FCF
- 9.79
- ROE
- 16.7%
- ROA
- 6.7%
- Debt/Equity
- 1.02
- Div yield
- 0.02%
As of Oct 22, 2026
8-K filings
Material corporate events ANI Pharmaceuticals, Inc. has disclosed to the SEC on Form 8-K.
- Board of directorsAug 24, 2026
On August 19, 2026, the Board of Directors (the "Board") of ANI Pharmaceuticals, Inc. (the "Company") appointed Henry Gosebruch to serve on the Board as a director with a term expiring at the Company's 2027 annual meeting of stockholders. Mr. Gosebruch, 53, has served as Chief Executive Officer and a member of the board of directors of Lakefront Biotherapeutics NV... Prior to Lakefront, Mr. Gosebruch served as President and Chief Executive Officer of Neumora Therapeutics, Inc.
- Investor communicationsAug 7, 2026
On August 7, 2026, the Company published an updated investor presentation to the investor relations section of its website. The Company may use the updated investor presentation in various meetings with investors and analysts from time to time.
- Shareholder meetingsMay 21, 2026
At the Annual Meeting, (i) each of the seven (7) director nominees were elected, (ii) the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified, (iii) the compensation of the Company's named executive officers was approved on an advisory basis, (iv) the stockholders voted, on an advisory basis, that future advisory votes to approve the compensation of the Company's named executive officers be held every one year, and (v) the Amended 2022 Stock Plan was approved.
- Investor communicationsMay 13, 2026
On May 13, 2026, ANI Pharmaceuticals, Inc. (the "Company") published an updated investor presentation to the investor relations section of its website. The Company may use the updated investor presentation in various meetings with investors and analysts from time to time.
- Auditor mattersApr 7, 2026
On April 1, 2026, the Audit Committee approved the appointment of Ernst & Young LLP ("EY"), effective April 1, 2026, as the Company's new independent registered public accounting firm for the fiscal year ended December 31, 2026. During the fiscal years ended December 31, 2025 and 2024 and the subsequent interim period through April 1, 2026, neither the Company nor anyone acting on its behalf consulted with EY regarding any of the matters referred to in Item 304(a)(2)(i) or (ii) of Regulation S-K.
Dividend history and stock splits
ANI Pharmaceuticals, Inc.'s recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 1-for-6Jun 4, 2012
ANIP short interest
How heavily ANIP is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 7.2
- Short interest
- 3.49M
- Avg volume
- 487.36K
As of · reported to FINRA twice monthly.
ANIP news
The latest news and headlines about ANI Pharmaceuticals, Inc. (ANIP).
- Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?positiveZacks Investment Research· Oct 13, 2026
- These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarpositiveZacks Investment Research· Oct 13, 2026
- How to Find Strong Medical Stocks Slated for Positive Earnings SurprisespositiveZacks Investment Research· Oct 6, 2026
- ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ETpositiveGlobeNewswire Inc.· Jul 24, 2026
- ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious UveitispositiveGlobeNewswire Inc.· Jul 13, 2026
Frequently asked questions
What is the ANI Pharmaceuticals, Inc. (ANIP) stock price today?
ANI Pharmaceuticals, Inc. (ANIP) is trading at $72.61 (-1.55% on the day) as of 5:53:17 PM EDT on Oct 23, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is ANI Pharmaceuticals, Inc.?
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology,…
What is the short interest in ANIP?
As of Sep 30, 2026, ANIP has 3.49M shares short and 7.2 days to cover.
What exchange is ANIP listed on?
ANI Pharmaceuticals, Inc. (ANIP) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of ANIP with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a ANIP analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.